CA3171186A1 - Transgenic animals expressing heavy chain antibodies - Google Patents
Transgenic animals expressing heavy chain antibodies Download PDFInfo
- Publication number
- CA3171186A1 CA3171186A1 CA3171186A CA3171186A CA3171186A1 CA 3171186 A1 CA3171186 A1 CA 3171186A1 CA 3171186 A CA3171186 A CA 3171186A CA 3171186 A CA3171186 A CA 3171186A CA 3171186 A1 CA3171186 A1 CA 3171186A1
- Authority
- CA
- Canada
- Prior art keywords
- gene
- segments
- human animal
- transgenic non
- transgenic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/102—Coronaviridae (F)
- C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Environmental Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Engineering & Computer Science (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063051180P | 2020-07-13 | 2020-07-13 | |
| US63/051,180 | 2020-07-13 | ||
| US202063076096P | 2020-09-09 | 2020-09-09 | |
| US63/076,096 | 2020-09-09 | ||
| PCT/CA2021/050951 WO2022011457A1 (en) | 2020-07-13 | 2021-07-12 | Transgenic animals expressing heavy chain antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3171186A1 true CA3171186A1 (en) | 2022-01-20 |
Family
ID=79555903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3171186A Pending CA3171186A1 (en) | 2020-07-13 | 2021-07-12 | Transgenic animals expressing heavy chain antibodies |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230270086A1 (https=) |
| EP (1) | EP4179095A4 (https=) |
| JP (1) | JP2023535345A (https=) |
| CN (1) | CN116193985A (https=) |
| CA (1) | CA3171186A1 (https=) |
| TW (1) | TWI908828B (https=) |
| WO (1) | WO2022011457A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025245358A1 (en) * | 2024-05-22 | 2025-11-27 | New York University | Genetically modified non-human animals producing heavy chain-only antibodies and methods of use |
| WO2025245494A1 (en) | 2024-05-24 | 2025-11-27 | Regeneron Pharmaceuticals, Inc. | Tumor-targeted split il12 receptor agonists |
| US20250376524A1 (en) | 2024-06-07 | 2025-12-11 | Regeneron Pharmaceuticals, Inc. | Tetravalent multispecific binding molecules and methods of use thereof |
| WO2025255452A2 (en) | 2024-06-07 | 2025-12-11 | Regeneron Pharmaceuticals, Inc. | Antigen-binding molecules that bind to aav particles and uses thereof |
| WO2026039791A1 (en) | 2024-08-16 | 2026-02-19 | Regeneron Pharmaceuticals, Inc. | Tumor-targeted split il2 receptor agonists |
| WO2026076013A1 (en) | 2024-10-01 | 2026-04-09 | Regeneron Pharmaceuticals, Inc. | Tumor-targeted il2 receptor agonists and multispecific t-cell engagers |
| WO2026075989A1 (en) | 2024-10-01 | 2026-04-09 | Regeneron Pharmaceuticals, Inc. | Engineered igg molecules and methods of use thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0110029D0 (en) * | 2001-04-24 | 2001-06-13 | Grosveld Frank | Transgenic animal |
| SI2311874T1 (sl) * | 2004-07-22 | 2017-12-29 | Erasmus University Medical Center Rotterdam Department of Cell Biology and Genetics | Vezavne molekule |
| TWI404727B (zh) * | 2006-01-25 | 2013-08-11 | 荷蘭鹿特丹Erasmus大學醫學中心 | 對偶基因排除 |
| US8754287B2 (en) * | 2009-12-10 | 2014-06-17 | Regeneron Pharmaceuticals, Inc. | Mice that make heavy chain antibodies |
| RU2664181C2 (ru) * | 2011-12-20 | 2018-08-15 | Регенерон Фармасьютикалз, Инк. | Мыши с гуманизированной легкой цепью |
| KR102276752B1 (ko) * | 2014-03-21 | 2021-07-13 | 리제너론 파마슈티칼스 인코포레이티드 | 단일 도메인 결합 단백질을 생산하는 비-인간 동물 |
| WO2018144097A1 (en) * | 2016-11-04 | 2018-08-09 | Akeagen Llc | Genetically modified non-human animals and methods for producing heavy chain-only antibodies |
| EP3332637A1 (en) * | 2016-12-09 | 2018-06-13 | Universitätsklinikum Hamburg-Eppendorf | Vhh-containing heavy chain antibody and production thereof |
| CA3102122A1 (en) * | 2018-06-13 | 2019-12-19 | Crystal Bioscience Inc. | Transgenic chicken with functionally deleted igy ch1 coding sequence |
| CA3204101A1 (en) * | 2020-12-09 | 2022-06-16 | Trianni, Inc. | Heavy chain-only antibodies |
-
2021
- 2021-07-12 US US18/015,304 patent/US20230270086A1/en active Pending
- 2021-07-12 CN CN202180060845.8A patent/CN116193985A/zh active Pending
- 2021-07-12 JP JP2023502801A patent/JP2023535345A/ja active Pending
- 2021-07-12 CA CA3171186A patent/CA3171186A1/en active Pending
- 2021-07-12 EP EP21843204.5A patent/EP4179095A4/en active Pending
- 2021-07-12 WO PCT/CA2021/050951 patent/WO2022011457A1/en not_active Ceased
- 2021-07-13 TW TW110125742A patent/TWI908828B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023535345A (ja) | 2023-08-17 |
| TWI908828B (zh) | 2025-12-21 |
| CN116193985A (zh) | 2023-05-30 |
| WO2022011457A1 (en) | 2022-01-20 |
| TW202215950A (zh) | 2022-05-01 |
| EP4179095A4 (en) | 2024-08-21 |
| US20230270086A1 (en) | 2023-08-31 |
| EP4179095A1 (en) | 2023-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230270088A1 (en) | Animal Models and Therapeutic Molecules | |
| US20230270086A1 (en) | Transgenic animals expressing heavy chain antibodies | |
| JP5909449B2 (ja) | 重鎖抗体を作製するマウス | |
| KR101481843B1 (ko) | 형질전환 동물 내에서의 중쇄만의 항체의 생성 | |
| US9220244B2 (en) | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies | |
| CN105753979B (zh) | 制造包含vl结构域的结合蛋白的小鼠 | |
| EP2785845A2 (en) | Functional isotype switching of chimaeric antibody chains & chimaeric animals expressing different igh isotypes | |
| JP2013513388A5 (https=) | ||
| JP7203731B2 (ja) | Vhh含有重鎖抗体およびその製造 | |
| NZ617158B2 (en) | Non-human animals expressing antibodies having a common light chain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220909 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20241230 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250428 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250428 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250528 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250528 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250619 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250619 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260310 |